EP1368485A2 - Process for the preparation of d-pantothenic acid and/or salts thereof - Google Patents

Process for the preparation of d-pantothenic acid and/or salts thereof

Info

Publication number
EP1368485A2
EP1368485A2 EP02706743A EP02706743A EP1368485A2 EP 1368485 A2 EP1368485 A2 EP 1368485A2 EP 02706743 A EP02706743 A EP 02706743A EP 02706743 A EP02706743 A EP 02706743A EP 1368485 A2 EP1368485 A2 EP 1368485A2
Authority
EP
European Patent Office
Prior art keywords
pantothenic acid
gene
microorganisms
codes
fermentation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02706743A
Other languages
German (de)
French (fr)
Inventor
Mechthild Rieping
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evonik Operations GmbH
Original Assignee
Degussa GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Degussa GmbH filed Critical Degussa GmbH
Publication of EP1368485A2 publication Critical patent/EP1368485A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C12P13/06—Alanine; Leucine; Isoleucine; Serine; Homoserine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
    • C12P7/42—Hydroxy-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/20—Flavobacterium

Definitions

  • This invention relates to a process for the fermentative preparation of D-pantothenic acid and/or salts thereof or mixtures containing these using microorganisms of the Enterobacteriaceae family in which at least the pckA gene is attenuated.
  • Pantothenic acid is produced worldwide in an order of magnitude of several thousand tons a year. It is used inter alia in human medicine, in the pharmaceuticals industry and in the foodstuffs industry. A large portion of the pantothenic acid produced is used for nutrition of stock animals such as poultry and pigs.
  • Pantothenic acid can be prepared by chemical synthesis, or biotechnologically by fermentation of suitable microorganisms in suitable nutrient solutions .
  • D -pantolactone is an important precursor. It is prepared in a multi-stage process from formaldehyde, isobutylaldehyde and cyanide, and in further process steps, the racemic mixture is separated, D- pantolactone is subjected to a condensation reaction with ⁇ -alanine, and D-pantothenic acid is obtained in this way.
  • the typical commercial form is the calcium salt of D- pantothenic acid.
  • the calcium salt of the racemic mixture of D,L-pantothenic acid is also customary.
  • the advantage of the fermentative preparation by microorganisms lies in the direct formation of the desired stereoisomeric form, that is to say the D-form, which is free from -pantothenic acid.
  • Various types of bacteria such as e.g. Escherichia coli (E. coli), Arthrobacter ureafaciens, Corynebacterium erythrogenes, Brevibacterium am oniagenes , and also yeasts, such as e.g. Debaromyces castellii, can produce D- pantothenic acid in a nutrient solution which comprises glucose, DL-pantoic acid and ⁇ -alanine, as shown in EP-A 0 493 060.
  • EP-A 0 493 060 furthermore shows that in the case of E. coli the formation of D-pantothenic acid is improved by amplification of pantothenic acid biosynthesis genes from E. coli which are contained on the plasmids pFV3 and pFV5 in a nutrient solution comprising glucose, DL- pantoic acid and ⁇ -alanine.
  • EP-A 0 590 857 and US Patent 5,518,906 describe mutants derived from E. coli strain IF03547, such as FV5714, FV525, FV814, FV521, FV221, FV6051 and FV5069, which carry resistances to various antimetabolites, such as salicylic acid, ⁇ -ketobutyric acid, ⁇ -hydroxyaspartic acid, 0- methylthreonine and ⁇ -ketoisovaleric acid. They produce pantoic acid in a nutrient solution comprising glucose, and D-pantothenic acid in a nutrient solution comprising glucose and ⁇ -alanine.
  • panB, panC and panD which are said to be contained on the plasmid pFV31, in the above-mentioned strains the production of D-pantoic acid in nutrient solutions comprising glucose and the production of D-pantothenic acid in a nutrient solution comprising glucose and ⁇ -alanine is improved.
  • D-pantothenic acid or the corresponding salt is isolated from the fermentation broth and purified (EP-A-0590857 and W096/33283) and accordingly used in purified form, or the fermentation broth comprising D-pantothenic acid is dried in total (EP-A-1050219) and used in particular as a feedstuffs additive.
  • the inventors had the object of providing new measures for improved fermentative preparation of D-pantothenic acid and/or salts thereof, and animal feedstuffs additives comprising these.
  • D-pantothenic acid or pantothenic acid or pantothenate are mentioned in the following text, this means not only the free acids but also the salts of D-pantothenic acid, such as e.g. the calcium, sodium, ammonium or potassium salt.
  • the invention provides a process for the fermentative preparation of D-pantothenic acid and/or salts thereof using microorganisms of the Enterobacteriaceae family which in particular already produce D-pantothenic acid and in ⁇ which the nucleotide sequence (s) which code(s) for the pckA gene are attenuated, in particular eliminated.
  • the process is a process which is characterized in that the following steps are carried out:
  • the invention also provides a process in which, after conclusion of the fermentation, all or some of the biomass remains in the fermentation broth, and the broth obtained in this way is processed, optionally after concentration, to a solid mixture which comprises D-pantothenic acid and/ or salts thereof and also comprises further constituents of the fermentation broth.
  • the term "attenuation" in this connection describes the reduction or elimination of the intracellular activity of one or more enzymes (proteins) in a microorganism which are coded by the corresponding DNA, for example by using a weak promoter or using a gene or allele which codes for a' corresponding enzyme (protein) with a low activity or inactivates . the corresponding gene or enzyme (protein) , and optionally combining these measures.
  • the activity or concentration of the corresponding protein is in general reduced to 0 to 75%, 0 to 50%, 0 to 25%, 0 to 10% or 0 to 5% of the activity or concentration of the wild-type protein or of the activity or concentration of the protein in the starting microorganism.
  • the microorganisms which the present invention provides can produce D-pantothenic acid from glucose, sucrose, lactose, fructose, maltose, molasses, starch, cellulose or from glycerol and ethanol . They are representatives of Enterobacteriaceae, in particular of the genus Escherichia. Of the genus Escherichia, the species Escherichia coli is to be mentioned in particular. Within the species Escherichia coli there may be mentioned the so-called K-12 strains, such as e. g. the strains MG1655 or W3110
  • Suitable D-pantothenic acid-producing strains of the genus Escherichia, in particular of the species Escherichia coli, are, for example
  • Enterobacteriaceae produce D- pantothenic acid in an improved manner after attenuation of the pckA gene, which codes for phosphoenol pyruvate carboxykinase (EC 4.1.1.49).
  • the nucleotide sequence of the pckA gene of Escherichia coli has been published by Medina et al. (Journal of Bacteriology 172, 7151-7156 (1990) and can also be found in the genome sequence of Escherichia coli published by
  • the pckA genes described in the text references mentioned can be used according to the invention. Alleles of the pckA gene which result from the degeneracy of the genetic code or due to sense mutations of neutral function can furthermore be used. To achieve an attenuation, for example, expression of the pckA gene or the catalytic properties of the enzyme protein can be reduced or eliminated. The two measures can optionally be cOmbined.
  • the reduction in gene expression can take place by suitable culturing, by genetic modification (mutation) of the signal structures of gene expression or also by the antisense-RNA technique.
  • Signal structures of gene expression are, for example, repressor genes, activator genes, operators, promoters, attenuators, ribosome binding sites, the start codon and terminators .
  • the expert can find in ormation in this respect, inter alia, for example, in Jensen and Hammer (Biotechnology and Bioengineering 58: 191-195 (1998)), in Carrier and Keasling (Biotechnology Progress 15, 58-64 (1999), Franch and Gerdes (Current Opinion.
  • Possible mutations are transitions, transversions, insertions and deletions .
  • "missense mutations” or "nonsense mutations” are referred to.
  • Insertions or deletions of at least one base pair in a gene lead to "frame shift mutations", which lead to incorrect a ino acids being incorporated or translation being interrupted prematurely.
  • Deletions of several codons typically lead to a complete loss of the enzyme activity. Instructions on generation of such mutations are prior art and can be found in known textbooks of genetics and molecular biology, such as e.g.
  • Suitable mutations in the pckA gene can be incorporated into suitable strains by gene or allele replacement.
  • a conventional method is the method, described by Hamilton et al. (Journal of Bacteriology 174, 4617 - 4622 (1989)), of gene replacement with the aid of a conditionally replicating pSClOl derivative pMAK705.
  • Other methods described in the prior art such as, for example, those of Martinez-Morales et al. (Journal of Bacteriology 1999, 7143-7148 (1999)) or those of Boyd et al . (Journal of
  • Bacteriology 182, 842-847 ⁇ (2000) ) can likewise be used.
  • D- pantothenic acid with strains of the Enterobacteriaceae family, in addition to the attenuation of the pckA gene, for one or more genes chosen from the group consisting of • the ilvGM operon which codes for acetohydroxy-acid synthase II (WO 97/10340)
  • panB gene which codes for ketopantoate hydroxymethyl transferase (US-A-5, 518, 906) ,
  • panE gene which codes for ketopantoate reductase
  • panD gene which codes for aspartate decarboxylase (US-A-5, 518, 906)
  • panC gene which codes for pantothenate synthetase (US-A-5, 518, 906)
  • enhancement in this connection describes the increase in the intracellular activity of one or more enzymes or proteins in a microorganism which are coded by the corresponding DNA, for example by increasing the number of copies of the gene or genes, using a potent promoter or a gene or allele which codes for a corresponding enzyme or protein with a high activity, and optionally combining these measures.
  • the activity or concentration of the corresponding protein is in general increased by at least 10%, 25%, 50%, 75%, 100%, 150%, 200%, 300%, 400% or 500%, up to a maximum of 1000% or 2000%, based on that of the wild-type protein or the activity or concentration of the protein in the starting microorganism.
  • the microorganisms produced according to the invention can be cultured in the batch process (batch culture) , the fed batch (feed process) or the repeated fed batch process (repetitive feed process) .
  • batch culture the fed batch
  • feed process the fed batch
  • repetitive feed process the repeated fed batch process
  • the culture medium to be used must meet the requirements of the particular strains in a suitable manner. Descriptions of culture media for various microorganisms are contained in the handbook "Manual of Methods for General Bacteriology” of the American Society for Bacteriology (Washington D.C., USA, 1981).
  • Sugars and carbohydrates such as e.g. glucose, sucrose, lactose, fructose, maltose, molasses, starch and cellulose, oils and fats, such as e.g. soya oil, sunflower oil, groundnut oil and coconut fat, fatty acids, such as e.g. palmitic acid, stearic acid and linoleic acid, alcohols, such as e.g. glycerol and ethanol, and organic acids, such as e.g. acetic acid, can be used as the source of carbon. These substances can be used individually or as a mixture.
  • Organic nitrogen-containing compounds such as peptones, yeast extract, meat extract, malt extract, corn steep liquor, soya bean flour and urea
  • inorganic compounds such as ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate and ammonium nitrate, can be used as the source of nitrogen.
  • the sources of nitrogen can be used individually or as a mixture.
  • Phosphoric acid, potassium dihydrogen phosphate or dipotassium hydrogen phosphate or the corresponding sodium- containing salts can be used as the source of phosphorus .
  • the culture medium must furthermore comprise salts of metals, such as e.g. magnesium sulfate or iron sulfate, which are necessary for growth.
  • essential growth substances such as a ino acids and vitamins, can be employed in addition to the above-mentioned substances .
  • Precursors of pantothenic acid, such as aspartate, ⁇ - alanine, ketoisovalerate, ketopantoic acid or pantoic acid and optionally salts thereof, can moreover be added to the culture medium.
  • the starting substances mentioned can be added to the culture in the form of a single batch, or can be fed in during the culture in a suitable manner.
  • Basic compounds such as sodium hydroxide, potassium hydroxide, ammonia or aqueous ammonia, or acid compounds, such as phosphoric acid or sulfuric acid, can be employed in a suitable manner to control the pH of the culture.
  • alkaline earth metal salts of pantothenic acid in particular the calcium salt
  • an inorganic compound containing an alkaline earth metal such as, for example, calcium hydroxide
  • an organic compound such as the alkaline earth metal salt of an organic acid, for example calcium acetate
  • the cation necessary for preparation of the desired alkaline earth metal salt of D-pantothenic acid is introduced into the fermentation broth directly in the desired amount, preferably in stoichiometric amounts.
  • Antifoams such as e.g. fatty acid polyglycol esters, can be employed to control the development of foam. Suitable substances having a selective action, e.g. antibiotics, can be added to the medium to maintain the stability of plasmids.
  • oxygen or oxygen- containing gas mixtures such as e.g. air, are introduced into the culture.
  • the temperature of the culture is usually 25 2 C to 45 2 C, and preferably 30 S C to 40 fi C. Culturing is continued until a maximum of D-pantothenic acid has formed. This target is usually reached within 10 hours to 160 hours.
  • the D-pantothenic acid' or the corresponding salts of D- pantothenic acid contained in the fermentation broth can then be isolated and purified in accordance with the prior art.
  • the fermentation broths comprising D-pantothenic acid and/or salts thereof preferably first to be freed from all or some of the biomass by known separation methods, such as, for example, centrifugation, filtration, decanting or a combination thereof.
  • separation methods such as, for example, centrifugation, filtration, decanting or a combination thereof.
  • the biomass in its entirety in the fermentation broth.
  • the suspension or solution is preferably concentrated and worked up to a powder, for example with the aid of a spray dryer or a freeze-drying unit. This powder is then in general converted by suitable compacting or granulating processes, e. g.
  • auxiliary substances or carriers such as starch, gelatin, cellulose derivatives or similar substances, such as are conventionally used as binders, gelling agents or thickeners in foodstuffs or feedstuffs processing, or further substances, such as, for example, silicas, silicates or stearates.
  • the fermentation product with or without further conventional fermentation constituents, can be absorbed on to an organic or inorganic carrier substance which is known and conventional in feedstuffs processing, such as, for example, silicas, silicates, grits, brans, meals, starches, sugars or others, and/or stabilized with conventional thickeners or binders .
  • feedstuffs processing such as, for example, silicas, silicates, grits, brans, meals, starches, sugars or others, and/or stabilized with conventional thickeners or binders .
  • D-Pantothenic acid or the desired salt of D-pantothenic acid or a formulation comprising these compounds is optionally added at a suitable process stage in order to achieve or establish the desired content of pantothenic acid or of the desired salt in the end product.
  • the desired content is in general in the range from 20 to 80 wt.% (dry mass) .
  • pantothenic acid can be determined with known chemical (Velisek; Chromatographic Science 60, 515-560 (1992)) or microbiological methods, such as e.g. the Lactobacillus plantarum test (DIFCO MANUAL, 10 th Edition, p. 1100-1102; Michigan, USA).
  • DSMZ German Collection Of Microorganisms and Cell Cultures, Braunschweig, Germany
  • PCR polymerase chain reaction
  • the chromosomal E. coli K12 MG1655 DNA employed for the PCR is isolated according to the manufacturers instructions with "Qiagen Genomic-tips 100/G" (QIAGEN, Hilden, Germany) .
  • Qiagen Genomic-tips 100/G QIAGEN, Hilden, Germany
  • pckl A DNA fragment approx. 500 bp in size from the 5' region of the pckA gene (called pckl) and a DNA fragment approx.
  • pck2 600 bp in size from the 3 ' region of the pckA gene (called pck2) can be amplified with the specific primers under standard PCR conditions (Innis et al. (1990) PCR Protocols. A Guide to Methods and Applications, Academic Press) with Taq-DNA polymerase (Gibco-BRL, Eggenstein, Germany) .
  • the PCR products are each ligated with the vector pCR2.1TOPO (TOPO TA Cloning Kit, Invitrogen, Groningen, The Netherlands) in accordance with the manufacturers instructions and transformed into the E. coli strain TOP10F' . Selection of plasmid-carrying cells takes place on LB agar, to which 50 ⁇ g/ l ampicillin are added.
  • the vector pCR2. lTOPOpck2 is cleaved with the restriction enzymes Stul and Xbal and, after separation in 0.8% agarose gel, the pck2 fragment is isolated with the aid of the QIAquick Gel Extraction Kit- (QIAGEN, Hilden, Germany) .
  • the vector pCR2. lTOPOpckl is cleaved with the enzymes EcoRV and Xbal and ligated with the pck2 fragment isolated.
  • the E. coli strain DH5 ⁇ is transformed with the ligation batch and plasmid-carrying cells are selected on LB agar, to which 50 ⁇ g/ml ampicillin is added.
  • plasmids in which the mutagenic DNA sequence shown in SEQ ID No. 7 is cloned are detected by control cleavage with the enzymes Spel and Xbal.
  • One of the plasmids is called pCR2.lTOPO ⁇ pckA.
  • the pckA allele described in example 1 is isolated from the vector pCR2. lTOPO ⁇ pckA after restriction with the enzymes Spel and Xbal and separation in 0.8% agarose gel, and ligated with the plasmid pMAK705 (Hamilton et al. (1989) Journal of Bacteriology 174, 4617 - 4622), which has been digested with the enzyme Xbal. The ligation batch is transformed in DH5 ⁇ and plasmid-carrying cells are selected on LB agar, to which 20 ⁇ g/ml chloramphenicol are added.
  • the L-threonine-producing E. coli strain MG442 is described in the patent specification US-A- 4,278,765 and deposited as CMIM B-1628 at the Russian National Collection for Industrial Microorganisms (VKPM, Moscow, Russia) .
  • MG442 is transformed with the plasmid pMAK705 ⁇ pckA, The gene replacement is carried out by the selection method described by Hamilton et al. (1989) Journal of Bacteriology 174, 4617 - 4622) and is verified by standard PCR methods (Innis et al. (1990) PCR Protocols. A Guide to Methods and Applications, Academic Press) with the following oligonucleotide primers:
  • pckA' 5' -1 5 - GATCCGAGCCTGACAGGTTA - 3* (SEQ ID No . 3)
  • MG442 contains the form of the ⁇ pckA allele shown in SEQ ID No. 8. The strain obtained is called MG442 ⁇ pckA.
  • the ilvGM operon from Escherichia coli IF03547 which codes for acetohydroxy acid synthase II is amplified using the polymerase chain reaction (PCR) and synthetic oligonucleotides.
  • PCR polymerase chain reaction
  • the sequence of the primer ilvGMl is chosen such that it contains an adenine at position 8.
  • a modified ribosome binding site is generated 7 nucleotides upstream of the start codon of the ilvG protein.
  • IlvGMl 5 ⁇ - CAGGACGAGGAACTAACTATG - 3' (SEQ ID ' No. 9)
  • IlvGM2 5 ⁇ - TCACGATGGCGGAATACAAC - 3 ⁇ (SEQ ID No. 10)
  • the chromosomal E. coli IF03547 DNA employed for the PCR is isolated according to the manufacturers instructions with "QIAGEN Genomic-tips 100/G" (QIAGEN, Hilden, Germany) .
  • a DNA fragment approx. 2100 bp in size, which comprises the modified ribosome binding site, the ilvGM coding regions and approx. 180 bp 3 '-flanking sequences, can be amplified with the specific primers under standard PCR conditions (Innis et al.: PCR Protocols. A Guide to Methods and Applications, 1990, Academic Press) with Pfu-DNA polymerase (Promega Corporation, Madison, USA) .
  • the PCR product is cloned in the plasmid pCR-Bluntll-TOPO and transformed in the E. coli strain TOP10 (Invitrogen, Groningen, The Netherlands, Product Description Zero Blunt TOPO PCR Cloning Kit, 1 Cat. No. K2800-20) .
  • Successful cloning is demonstrated by cleavage of the plasmid pCR- BluntIF03547ilvGM with the restriction enzymes EcoRI and Sphl.
  • the plasmid DNA is isolated by means of the "QIAprep Spin Plasmid Kit" (QIAGEN, Hilden, Germany) and, after cleavage, separated in a 0.8 % agarose gel.
  • the DNA sequence of the amplified fragment is determined using the reverse and universal sequencing primer (QIAGEN, Hilden, Germany) .
  • the sequence of the PCR product is shown in SEQ ID No. 11 and 13.
  • the ilvG gene or allele is identified in SEQ ID No. 11.
  • the ilvM gene or allele is identified in SEQ ID No. 13.
  • the associated gene products or proteins are shown in SEQ ID No. 12 and 14. 4.2 Cloning of the ilvGM gene in the expression vector pTrc99A
  • the ilvGM genes described in example 4.1 are cloned in the vector pTrc99A (Amersham Pharmacia Biotech Inc, Uppsala, Sweden) for expression in Escherichia coli K12.
  • the plasmid pCR-BluntIF03547ilvGM is cleaved with the enzyme EcoRI, the cleavage batch is separated in 0.8% agarose gel and the ilvGM fragment 2.1 kbp in size is isolated with the aid of the QIAquick Gel Extraction Kit (QIAGEN, Hilden, Germany) .
  • the vector pTrc99A is cleaved with the enzyme EcoRI, an alkaline phosphatase treatment is carried out, and ligation is carried out with the ilvGM fragment isolated.
  • the ligation batch is transformed in the E. coli strain DH5 ⁇ .
  • Selection of pTrc99A-carrying cells is carried out on LB agar (Lennox, Virology 1:190 (1955)), to which 50 ⁇ g/ml ampicillin is added. Successful cloning of the ilvGM operon can be demonstrated after plasmid DNA isolation and control cleavage with Sail and Sphl.
  • pTrc99AilvGM (figure 2)
  • expression of the ilvGM operon is regulated by the Ptrc promoter lying upstream of the modified ribosome binding site and by the rRNA terminator region lying downstream of the ilvGM coding region.
  • the E. coli strain FV5069/pFV31 which produces D- pantothenic acid is described in EP-A-0590857 and deposited as FERM BP 4395 in accordance with the Budapest Treaty.
  • the plasmid pFV31 is isolated from FV5069/pFV31, cleaved with the enzyme BamHI, and the projecting 3' ends are treated with Klenow enzyme. An alkaline phosphatase treatment is then carried out.
  • the ilvGM expression cassette 2.8 kbp in size is isolated and ligated with the linearized and dephosphorylated vector pFV31.
  • the ligation batch is transformed in the E. coli strain DH5 ⁇ and plasmid-carrying cells are selected on LB agar, to which 50 ⁇ g/ml ampicillin are added.
  • Successful cloning of the ilvGM expression cassette can be demonstrated after plasmid DNA isolation and control cleavage with Hindl l, Sail, Smal, Sphl and Xbal.
  • the plasmid is called pFV31ilvGM (figure 3).
  • the strain MG442 ⁇ pckA obtained in example 3 and the strain MG442 are transformed with the plasmid pFV31ilvGM and transformants are selected on LB agar, which is supplemented with 50 ⁇ g/ml ampicillin.
  • the strains MG442 ⁇ pckA/pFV31ilvGM and MG4 2/pFV31ilvGM are formed in this manner.
  • pantothenate production of the E. coli strains MG442/pFV31ilvGM and MG442 ⁇ pckA/pFV31ilvGM is checked in batch cultures of 10 ml contained in 100 ml conical flasks.
  • panB Coding region of the panB gene
  • panC Coding region of the panC gene
  • the microorganism identified under I. above was accompanied by:
  • This International Depositary Authority accepts the microorganism identified under I. above, which was received by it on 2000 - 10 - 02 (Date of the original deposit) 1 .
  • microorganism identified under I above was received by this International Depositary Authority on (date of original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on (dale of receipt of request for conversion).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The invention provides a process for the preparation of D-pantothenic acid and/or salts thereof or feedstuffs additives comprising these by fermentation of microorganisms of the Enterobacteriaceae family, in particular those which already produce D-pantothenic acid, characterized in that the nucleotide sequence(s) in the microorganisms which code(s) for the pckA gene is (are) attenuated, in particular eliminated.

Description

Process for the Preparation of D-Pantothenic Acid and/or Salts thereof
Field of the Invention
This invention relates to a process for the fermentative preparation of D-pantothenic acid and/or salts thereof or mixtures containing these using microorganisms of the Enterobacteriaceae family in which at least the pckA gene is attenuated.
Prior Art
Pantothenic acid is produced worldwide in an order of magnitude of several thousand tons a year. It is used inter alia in human medicine, in the pharmaceuticals industry and in the foodstuffs industry. A large portion of the pantothenic acid produced is used for nutrition of stock animals such as poultry and pigs.
Pantothenic acid can be prepared by chemical synthesis, or biotechnologically by fermentation of suitable microorganisms in suitable nutrient solutions . In the chemical synthesis, D -pantolactone is an important precursor. It is prepared in a multi-stage process from formaldehyde, isobutylaldehyde and cyanide, and in further process steps, the racemic mixture is separated, D- pantolactone is subjected to a condensation reaction with β-alanine, and D-pantothenic acid is obtained in this way.
The typical commercial form is the calcium salt of D- pantothenic acid. The calcium salt of the racemic mixture of D,L-pantothenic acid is also customary.
The advantage of the fermentative preparation by microorganisms lies in the direct formation of the desired stereoisomeric form, that is to say the D-form, which is free from -pantothenic acid. Various types of bacteria, such as e.g. Escherichia coli (E. coli), Arthrobacter ureafaciens, Corynebacterium erythrogenes, Brevibacterium am oniagenes , and also yeasts, such as e.g. Debaromyces castellii, can produce D- pantothenic acid in a nutrient solution which comprises glucose, DL-pantoic acid and β-alanine, as shown in EP-A 0 493 060. EP-A 0 493 060 furthermore shows that in the case of E. coli the formation of D-pantothenic acid is improved by amplification of pantothenic acid biosynthesis genes from E. coli which are contained on the plasmids pFV3 and pFV5 in a nutrient solution comprising glucose, DL- pantoic acid and β-alanine.
EP-A 0 590 857 and US Patent 5,518,906 describe mutants derived from E. coli strain IF03547, such as FV5714, FV525, FV814, FV521, FV221, FV6051 and FV5069, which carry resistances to various antimetabolites, such as salicylic acid, α-ketobutyric acid, β-hydroxyaspartic acid, 0- methylthreonine and α-ketoisovaleric acid. They produce pantoic acid in a nutrient solution comprising glucose, and D-pantothenic acid in a nutrient solution comprising glucose and β-alanine. It is furthermore stated in EP-A 0 590 857 and US Patent 5,518,906 that after amplification of the pantothenic acid biosynthesis genes panB, panC and panD, which are said to be contained on the plasmid pFV31, in the above-mentioned strains the production of D-pantoic acid in nutrient solutions comprising glucose and the production of D-pantothenic acid in a nutrient solution comprising glucose and β-alanine is improved.
The favorable effect of enhancement of the ilvGM operon on production of D-pantothenic acid is furthermore reported in
WO97/10340. Finally, the effect of enhancement of the panE gene on the formation of D-pantothenic acid is reported in EP-A-1001027.
According to the prior art, D-pantothenic acid or the corresponding salt is isolated from the fermentation broth and purified (EP-A-0590857 and W096/33283) and accordingly used in purified form, or the fermentation broth comprising D-pantothenic acid is dried in total (EP-A-1050219) and used in particular as a feedstuffs additive.
Object of the Invention
The inventors had the object of providing new measures for improved fermentative preparation of D-pantothenic acid and/or salts thereof, and animal feedstuffs additives comprising these.
Summary of the Invention
When D-pantothenic acid or pantothenic acid or pantothenate are mentioned in the following text, this means not only the free acids but also the salts of D-pantothenic acid, such as e.g. the calcium, sodium, ammonium or potassium salt.
The invention provides a process for the fermentative preparation of D-pantothenic acid and/or salts thereof using microorganisms of the Enterobacteriaceae family which in particular already produce D-pantothenic acid and in < which the nucleotide sequence (s) which code(s) for the pckA gene are attenuated, in particular eliminated.
In particular, the process is a process which is characterized in that the following steps are carried out:
a) fermentation of microorganisms of the Enterobacteriaceae family in which the pckA gene is attenuated, optionally in combination with attenuation or enhancement of further genes, and
b) optionally in the presence of alkaline earth metal compounds, these being added continuously or discontinuously in preferably stoichiometric amounts, c) concentration of the D-pantothenic acid or of the corresponding salt in the medium or the fermentation broth or in the cells of the microorganisms of the Enterobacteriaceae family and
d) after conclusion of the fermentation, isolation of the D-pantothenic acid, and/or of the corresponding salt.
The invention also provides a process in which, after conclusion of the fermentation, all or some of the biomass remains in the fermentation broth, and the broth obtained in this way is processed, optionally after concentration, to a solid mixture which comprises D-pantothenic acid and/ or salts thereof and also comprises further constituents of the fermentation broth.
Detailed Description of the Invention
The term "attenuation" in this connection describes the reduction or elimination of the intracellular activity of one or more enzymes (proteins) in a microorganism which are coded by the corresponding DNA, for example by using a weak promoter or using a gene or allele which codes for a' corresponding enzyme (protein) with a low activity or inactivates . the corresponding gene or enzyme (protein) , and optionally combining these measures.
By attenuation measures, including reduction in expression, the activity or concentration of the corresponding protein is in general reduced to 0 to 75%, 0 to 50%, 0 to 25%, 0 to 10% or 0 to 5% of the activity or concentration of the wild-type protein or of the activity or concentration of the protein in the starting microorganism.
The microorganisms which the present invention provides can produce D-pantothenic acid from glucose, sucrose, lactose, fructose, maltose, molasses, starch, cellulose or from glycerol and ethanol . They are representatives of Enterobacteriaceae, in particular of the genus Escherichia. Of the genus Escherichia, the species Escherichia coli is to be mentioned in particular. Within the species Escherichia coli there may be mentioned the so-called K-12 strains, such as e. g. the strains MG1655 or W3110
(Neidhard et al.: Escherichia coli and Salmonella. Cellular and Molecular Biology (ASM Press, Washington D.C.)) or the Escherichia coli wild type strain IF03547 (Institute of Fermentation, Osaka, Japan) and mutants derived from these which have the ability to produce D-pantothenic acid.
Suitable D-pantothenic acid-producing strains of the genus Escherichia, in particular of the species Escherichia coli, are, for example
Escherichia coli FV5069/pFV31 Escherichia coli FV5069/pFV202
Escherichia coli FE6/pFE80 and Escherichia coli KE3
It has been found that Enterobacteriaceae produce D- pantothenic acid in an improved manner after attenuation of the pckA gene, which codes for phosphoenol pyruvate carboxykinase (EC 4.1.1.49).
The nucleotide sequence of the pckA gene of Escherichia coli has been published by Medina et al. (Journal of Bacteriology 172, 7151-7156 (1990) and can also be found in the genome sequence of Escherichia coli published by
Blattner et al. (Science 277, 1453 - 1462 (1997) under Accession Number AE000416.
The pckA genes described in the text references mentioned can be used according to the invention. Alleles of the pckA gene which result from the degeneracy of the genetic code or due to sense mutations of neutral function can furthermore be used. To achieve an attenuation, for example, expression of the pckA gene or the catalytic properties of the enzyme protein can be reduced or eliminated. The two measures can optionally be cOmbined.
The reduction in gene expression can take place by suitable culturing, by genetic modification (mutation) of the signal structures of gene expression or also by the antisense-RNA technique. Signal structures of gene expression are, for example, repressor genes, activator genes, operators, promoters, attenuators, ribosome binding sites, the start codon and terminators . The expert can find in ormation in this respect, inter alia, for example, in Jensen and Hammer (Biotechnology and Bioengineering 58: 191-195 (1998)), in Carrier and Keasling (Biotechnology Progress 15, 58-64 (1999), Franch and Gerdes (Current Opinion. in Microbiology 3, 159-164 (2000)) and in known textbooks of genetics and molecular biology, such as, for example, the textbook of Knippers ( "Molekulare Genetik [Molecular Genetics]", 6th edition, Georg Thie e Verlag, Stuttgart, Germany, 1995) or that of Winnacker ("Gene und Klone [Genes and Clones]", VCH Verlagsgesellschaft, Weinheim, Germany, 1990) .
Mutations which lead to a change or reduction in the catalytic properties of enzyme proteins are known from the prior art. Examples which may be,mentioned are the works of Qiu and Goodman (Journal of Biological Chemistry 272: 8611- 8617 (1997)), Yano et al. (Proceedings of the National Academy of Sciences, USA 95, 5511-5515 (1998), Wente and Schachmann (Journal of Biological Chemistry 266, 20833- 20839 (1991) . Summarizing descriptions can be found in known textbooks of genetics and molecular biology, such as e.g. that by Hagemann ("Allgemeine Genetik [General Genetics]", Gustav Fischer Verlag, Stuttgart, 1986).
Possible mutations are transitions, transversions, insertions and deletions . Depending on the effect of the arαino acid exchange on the enzyme activity, "missense mutations" or "nonsense mutations" are referred to. Insertions or deletions of at least one base pair in a gene, lead to "frame shift mutations", which lead to incorrect a ino acids being incorporated or translation being interrupted prematurely. Deletions of several codons typically lead to a complete loss of the enzyme activity. Instructions on generation of such mutations are prior art and can be found in known textbooks of genetics and molecular biology, such as e.g. the textbook by Knippers ( "Molekulare Genetik [Molecular Genetics]", 6th edition, Georg Thieme Verlag, Stuttgart, Germany, 1995) , that by Winnacker ("Gene und Klone [Genes and Clones]", VCH Verlagsgesellschaft, Weinheim, Germany, 1990) or that by Hagemann ("Allgemeine Genetik [General Genetics]", Gustav Fischer Verlag, Stuttgart, 1986) .
Suitable mutations in the pckA gene, such as, for example, deletion mutations, can be incorporated into suitable strains by gene or allele replacement.
A conventional method is the method, described by Hamilton et al. (Journal of Bacteriology 174, 4617 - 4622 (1989)), of gene replacement with the aid of a conditionally replicating pSClOl derivative pMAK705. Other methods described in the prior art, such as, for example, those of Martinez-Morales et al. (Journal of Bacteriology 1999, 7143-7148 (1999)) or those of Boyd et al . (Journal of
Bacteriology 182, 842-847 ■ (2000) ) , can likewise be used.
It is also possible to transfer mutations in the pckA gene or mutations which affect expression of the pckA gene into various strains by conjugation or transduction.
It may furthermore be advantageous for the production of D- pantothenic acid with strains of the Enterobacteriaceae family, in addition to the attenuation of the pckA gene, for one or more genes chosen from the group consisting of • the ilvGM operon which codes for acetohydroxy-acid synthase II (WO 97/10340)
• the panB gene which codes for ketopantoate hydroxymethyl transferase (US-A-5, 518, 906) ,
• the panE gene which codes for ketopantoate reductase (EP-A-1001027)
• the panD gene which codes for aspartate decarboxylase (US-A-5, 518, 906)
• the panC gene which codes for pantothenate synthetase (US-A-5, 518, 906)
• the serC gene which codes for phosphoserine transaminase (Duncan and Coggins, Biochemical Journal 234:49-57 (1986)),
• the gcvT, gcvH and gcvP genes which code for the glycine cleavage system (Okamura-Ikeda et al . , European Journal of Biochemistry 216, 539-548 (1993)), and
• the glyA gene which codes for serine hydroxymethyl transferase (Plamann et al (Nucleic Acids Research 11(7) :2065 -2075(1983) ) )
to be enhanced, in particular over-expressed.
The term "enhancement" in this connection describes the increase in the intracellular activity of one or more enzymes or proteins in a microorganism which are coded by the corresponding DNA, for example by increasing the number of copies of the gene or genes, using a potent promoter or a gene or allele which codes for a corresponding enzyme or protein with a high activity, and optionally combining these measures.
By enhancement measures, in particular over-expression, the activity or concentration of the corresponding protein is in general increased by at least 10%, 25%, 50%, 75%, 100%, 150%, 200%, 300%, 400% or 500%, up to a maximum of 1000% or 2000%, based on that of the wild-type protein or the activity or concentration of the protein in the starting microorganism.
Finally, it may be advantageous for the production of D- pantothenic acid with strains of the Enterobacteriaceae family, in addition to the attenuation of the pckA gene, for
• the avtA gene which codes for transaminase C (EP-A- 1001027) and
• the poxB gene which codes for pyruvate oxidase (Grabau and Cronan, Nucleic Acids Research. 14 (13), 5449-5460 (1986))
to be attenuated, in particular eliminated or expressed at a low level .
In addition to the attenuation of the pckA gene it may furthermore be advantageous for the production of D- pantothenic acid to eliminate undesirable side reactions (Nakayama: "Breeding of Amino Acid Producing
Microorganisms", in: Overproduction of Microbial Products, Kru phanzl, Siky a, Van'ek (eds.), Academic Press, London, UK, 1982) . Bacteria in which the metabolic pathways which reduce the formation of D-pantothenic acid are at least partly eliminated can be employed in the process according to the invention.
The microorganisms produced according to the invention can be cultured in the batch process (batch culture) , the fed batch (feed process) or the repeated fed batch process (repetitive feed process) . A summary of known culture methods is described in the textbook by Chmiel (Bioprozesstechnik 1. Einfϋhrung in die Bioverfahrenstechnik [Bioprocess Technology 1. Introduction to Bioprocess Technology (Gustav Fischer Verlag, Stuttgart, 1991)) or in the textbook by Storhas (Bioreaktoren und periphere Einrichtungen [Bioreactors and Peripheral Equipment] (Vieweg Verlag, Braunschweig/Wiesbaden, 1994)).
The culture medium to be used must meet the requirements of the particular strains in a suitable manner. Descriptions of culture media for various microorganisms are contained in the handbook "Manual of Methods for General Bacteriology" of the American Society for Bacteriology (Washington D.C., USA, 1981). Sugars and carbohydrates, such as e.g. glucose, sucrose, lactose, fructose, maltose, molasses, starch and cellulose, oils and fats, such as e.g. soya oil, sunflower oil, groundnut oil and coconut fat, fatty acids, such as e.g. palmitic acid, stearic acid and linoleic acid, alcohols, such as e.g. glycerol and ethanol, and organic acids, such as e.g. acetic acid, can be used as the source of carbon. These substances can be used individually or as a mixture.
Organic nitrogen-containing compounds, such as peptones, yeast extract, meat extract, malt extract, corn steep liquor, soya bean flour and urea, or inorganic compounds, such as ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate and ammonium nitrate, can be used as the source of nitrogen. The sources of nitrogen can be used individually or as a mixture.
Phosphoric acid, potassium dihydrogen phosphate or dipotassium hydrogen phosphate or the corresponding sodium- containing salts can be used as the source of phosphorus . The culture medium must furthermore comprise salts of metals, such as e.g. magnesium sulfate or iron sulfate, which are necessary for growth. Finally, essential growth substances, such as a ino acids and vitamins, can be employed in addition to the above-mentioned substances . Precursors of pantothenic acid, such as aspartate, β- alanine, ketoisovalerate, ketopantoic acid or pantoic acid and optionally salts thereof, can moreover be added to the culture medium. The starting substances mentioned can be added to the culture in the form of a single batch, or can be fed in during the culture in a suitable manner.
Basic compounds, such as sodium hydroxide, potassium hydroxide, ammonia or aqueous ammonia, or acid compounds, such as phosphoric acid or sulfuric acid, can be employed in a suitable manner to control the pH of the culture.
For the preparation of alkaline earth metal salts of pantothenic acid, in particular the calcium salt, it is equally possible to add the suspension or solution of an inorganic compound containing an alkaline earth metal, such as, for example, calcium hydroxide, or of an organic compound, such as the alkaline earth metal salt of an organic acid, for example calcium acetate, continuously or discontinuously during the fermentation. In this manner, the cation necessary for preparation of the desired alkaline earth metal salt of D-pantothenic acid is introduced into the fermentation broth directly in the desired amount, preferably in stoichiometric amounts.
Antifoams, such as e.g. fatty acid polyglycol esters, can be employed to control the development of foam. Suitable substances having a selective action, e.g. antibiotics, can be added to the medium to maintain the stability of plasmids. To maintain aerobic conditions, oxygen or oxygen- containing gas mixtures, such as e.g. air, are introduced into the culture. The temperature of the culture is usually 252C to 452C, and preferably 30SC to 40fiC. Culturing is continued until a maximum of D-pantothenic acid has formed. This target is usually reached within 10 hours to 160 hours.
The D-pantothenic acid' or the corresponding salts of D- pantothenic acid contained in the fermentation broth can then be isolated and purified in accordance with the prior art.
It is also possible for the fermentation broths comprising D-pantothenic acid and/or salts thereof preferably first to be freed from all or some of the biomass by known separation methods, such as, for example, centrifugation, filtration, decanting or a combination thereof. However, it is also possible to leave the biomass in its entirety in the fermentation broth. In general, the suspension or solution is preferably concentrated and worked up to a powder, for example with the aid of a spray dryer or a freeze-drying unit. This powder is then in general converted by suitable compacting or granulating processes, e. g. also build-up granulation, into a coarser-grained, free-flowing, storable and largely dust-free product with the desired particle size distribution of optionally 20 to 2000 μm. In the granulation or compacting it is advantageous to employ conventional organic or inorganic auxiliary substances or carriers, such as starch, gelatin, cellulose derivatives or similar substances, such as are conventionally used as binders, gelling agents or thickeners in foodstuffs or feedstuffs processing, or further substances, such as, for example, silicas, silicates or stearates.
Alternatively, the fermentation product, with or without further conventional fermentation constituents, can be absorbed on to an organic or inorganic carrier substance which is known and conventional in feedstuffs processing, such as, for example, silicas, silicates, grits, brans, meals, starches, sugars or others, and/or stabilized with conventional thickeners or binders . Use examples and processes in this context are described in the literature (Die Muhle + Mischfuttertechnik 132 (1995) 49, page 817).
D-Pantothenic acid or the desired salt of D-pantothenic acid or a formulation comprising these compounds is optionally added at a suitable process stage in order to achieve or establish the desired content of pantothenic acid or of the desired salt in the end product.
The desired content is in general in the range from 20 to 80 wt.% (dry mass) .
The concentration of pantothenic acid can be determined with known chemical (Velisek; Chromatographic Science 60, 515-560 (1992)) or microbiological methods, such as e.g. the Lactobacillus plantarum test (DIFCO MANUAL, 10th Edition, p. 1100-1102; Michigan, USA).
A pure culture of the Escherichia coli K-12 strain DH5 /pMAK705 was deposited as DSM 13720 on 8th September 2000 at the Deutsche Sammlung fur Mikroorganismen und Zellkulturen (DSMZ = German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany) in accordance with the Budapest Treaty.
A pure culture of the Escherichia coli K-12 strain MG442ΔpckA was deposited as DSM 13761 on 2nd October 2000 at the Deutsche Sammlung fur Mikroorganismen und Zellkulturen (DSMZ = German Collection Of Microorganisms and Cell Cultures, Braunschweig, Germany) in accordance with the Budapest Treaty.
The present invention is explained in more detail in the following with the aid of embodiment examples.
The isolation of plasmid DNA from Escherichia coli and all techniques of restriction, Klenow and alkaline phosphatase treatment are carried out by the method of Sambrook et al .
(Molecular cloning - A Laboratory Manual (1989) Cold Spring
Harbor Laboratory Press) . Unless described otherwise, the transformation of Escherichia coli is carried out by the method of Chung et al. (Proceedings of the National Academy of Sciences of the United States of America USA (1989) 86: 2172-2175) . The incubation temperature for the preparation of strains and transformants is 372C. Temperatures of 30eC and 442C are used in the gene replacement method of Hamilton et. al .
Example 1
Construction of the deletion mutation of the pckA gene
Parts of the 5 ' and 3 ' region of the pckA gene are amplified from Escherichia coli K12 using the polymerase chain reaction (PCR) and synthetic oligonucleotides . Starting from the nucleotide sequence of the pckA gene in E. coli K12 MG1655 (SEQ ID No. 1), the following PCR primers are synthesized (MWG Biotech, Ebersberg, Germany) :
pckA»5x-l: 5X - GATCCGAGCCTGACAGGTTA - 3λ (SEQ ID No . 3)
pckAλ5λ-2: 5λ - GCATGCGCTCGGTCAGGTTA - 3λ (SEQ ID No. 4)
pckAΛ3Λ-l: 5 - AGGCCTGAAGATGGCACTATCG - 3' (SEQ ID No . 5)
pckAλ3λ-2: 5 - CCGGAGAAGCGTAGGTGTTA - 3* (SEQ ID No . 6)
The chromosomal E. coli K12 MG1655 DNA employed for the PCR is isolated according to the manufacturers instructions with "Qiagen Genomic-tips 100/G" (QIAGEN, Hilden, Germany) . A DNA fragment approx. 500 bp in size from the 5' region of the pckA gene (called pckl) and a DNA fragment approx.
600 bp in size from the 3 ' region of the pckA gene (called pck2) can be amplified with the specific primers under standard PCR conditions (Innis et al. (1990) PCR Protocols. A Guide to Methods and Applications, Academic Press) with Taq-DNA polymerase (Gibco-BRL, Eggenstein, Germany) . The PCR products are each ligated with the vector pCR2.1TOPO (TOPO TA Cloning Kit, Invitrogen, Groningen, The Netherlands) in accordance with the manufacturers instructions and transformed into the E. coli strain TOP10F' . Selection of plasmid-carrying cells takes place on LB agar, to which 50 μg/ l ampicillin are added. After isolation of the plasmid DNA, the vector pCR2. lTOPOpck2 is cleaved with the restriction enzymes Stul and Xbal and, after separation in 0.8% agarose gel, the pck2 fragment is isolated with the aid of the QIAquick Gel Extraction Kit- (QIAGEN, Hilden, Germany) . After isolation of the plasmid DNA the vector pCR2. lTOPOpckl is cleaved with the enzymes EcoRV and Xbal and ligated with the pck2 fragment isolated. The E. coli strain DH5α is transformed with the ligation batch and plasmid-carrying cells are selected on LB agar, to which 50 μg/ml ampicillin is added. After isolation of the plasmid DNA those plasmids in which the mutagenic DNA sequence shown in SEQ ID No. 7 is cloned are detected by control cleavage with the enzymes Spel and Xbal. One of the plasmids is called pCR2.lTOPOΔpckA.
Example 2
Construction of the replacement vector pMAK705ΔpckA
The pckA allele described in example 1 is isolated from the vector pCR2. lTOPOΔpckA after restriction with the enzymes Spel and Xbal and separation in 0.8% agarose gel, and ligated with the plasmid pMAK705 (Hamilton et al. (1989) Journal of Bacteriology 174, 4617 - 4622), which has been digested with the enzyme Xbal. The ligation batch is transformed in DH5α and plasmid-carrying cells are selected on LB agar, to which 20 μg/ml chloramphenicol are added. Successful cloning is demonstrated after isolation of the plasmid DNA and cleavage with the enzymes Hpal, Kpnl, Hindlll, Sail and Pstl. The replacement vector formed, pMAK705ΔpckA (= pMAK705deltapckA) , is shown in figure 1. Example 3
Position-specific mutagenesis of the pckA gene in the E. coli strain MG442
The L-threonine-producing E. coli strain MG442 is described in the patent specification US-A- 4,278,765 and deposited as CMIM B-1628 at the Russian National Collection for Industrial Microorganisms (VKPM, Moscow, Russia) .
For replacement of the chromosomal pckA gene with the plasmid-coded deletion construct, MG442 is transformed with the plasmid pMAK705ΔpckA, The gene replacement is carried out by the selection method described by Hamilton et al. (1989) Journal of Bacteriology 174, 4617 - 4622) and is verified by standard PCR methods (Innis et al. (1990) PCR Protocols. A Guide to Methods and Applications, Academic Press) with the following oligonucleotide primers:
pckA' 5' -1: 5 - GATCCGAGCCTGACAGGTTA - 3* (SEQ ID No . 3)
pckAx3Λ-2: 5λ - CCGGAGAAGCGTAGGTGTTA - 3λ (SEQ ID No. 6)
After replacement has taken place, MG442 contains the form of the ΔpckA allele shown in SEQ ID No. 8. The strain obtained is called MG442ΔpckA.
Example 4
Preparation of D-pantothenic acid with the strain MG442ΔpckA/pFV31ilvGM
4.1 Amplification and cloning of the ilvGM gene
The ilvGM operon from Escherichia coli IF03547 which codes for acetohydroxy acid synthase II (Institut fur Fermentation [Institute of Fermentation] , Osaka, Japan) is amplified using the polymerase chain reaction (PCR) and synthetic oligonucleotides. Starting from the nucleotide sequence of the ilvGM operon in E. coli K12 MG1655 (GenBank: Accession No. M87049) , PCR primers are synthesized, (MWG Biotech, Ebersberg, Germany) . The sequence of the primer ilvGMl is chosen such that it contains an adenine at position 8. As a result, a modified ribosome binding site is generated 7 nucleotides upstream of the start codon of the ilvG protein.
IlvGMl: 5λ - CAGGACGAGGAACTAACTATG - 3' (SEQ ID 'No. 9)
IlvGM2: 5λ - TCACGATGGCGGAATACAAC - 3Λ(SEQ ID No. 10)
The chromosomal E. coli IF03547 DNA employed for the PCR is isolated according to the manufacturers instructions with "QIAGEN Genomic-tips 100/G" (QIAGEN, Hilden, Germany) . A DNA fragment approx. 2100 bp in size, which comprises the modified ribosome binding site, the ilvGM coding regions and approx. 180 bp 3 '-flanking sequences, can be amplified with the specific primers under standard PCR conditions (Innis et al.: PCR Protocols. A Guide to Methods and Applications, 1990, Academic Press) with Pfu-DNA polymerase (Promega Corporation, Madison, USA) . The PCR product is cloned in the plasmid pCR-Bluntll-TOPO and transformed in the E. coli strain TOP10 (Invitrogen, Groningen, The Netherlands, Product Description Zero Blunt TOPO PCR Cloning Kit,1 Cat. No. K2800-20) . Successful cloning is demonstrated by cleavage of the plasmid pCR- BluntIF03547ilvGM with the restriction enzymes EcoRI and Sphl. For this, the plasmid DNA is isolated by means of the "QIAprep Spin Plasmid Kit" (QIAGEN, Hilden, Germany) and, after cleavage, separated in a 0.8 % agarose gel. The DNA sequence of the amplified fragment is determined using the reverse and universal sequencing primer (QIAGEN, Hilden, Germany) . The sequence of the PCR product is shown in SEQ ID No. 11 and 13. The ilvG gene or allele is identified in SEQ ID No. 11. The ilvM gene or allele is identified in SEQ ID No. 13. The associated gene products or proteins are shown in SEQ ID No. 12 and 14. 4.2 Cloning of the ilvGM gene in the expression vector pTrc99A
The ilvGM genes described in example 4.1 are cloned in the vector pTrc99A (Amersham Pharmacia Biotech Inc, Uppsala, Sweden) for expression in Escherichia coli K12. For this, the plasmid pCR-BluntIF03547ilvGM is cleaved with the enzyme EcoRI, the cleavage batch is separated in 0.8% agarose gel and the ilvGM fragment 2.1 kbp in size is isolated with the aid of the QIAquick Gel Extraction Kit (QIAGEN, Hilden, Germany) . The vector pTrc99A is cleaved with the enzyme EcoRI, an alkaline phosphatase treatment is carried out, and ligation is carried out with the ilvGM fragment isolated. The ligation batch is transformed in the E. coli strain DH5α. Selection of pTrc99A-carrying cells is carried out on LB agar (Lennox, Virology 1:190 (1955)), to which 50μg/ml ampicillin is added. Successful cloning of the ilvGM operon can be demonstrated after plasmid DNA isolation and control cleavage with Sail and Sphl. In the vector, which is called pTrc99AilvGM (figure 2), expression of the ilvGM operon is regulated by the Ptrc promoter lying upstream of the modified ribosome binding site and by the rRNA terminator region lying downstream of the ilvGM coding region.
4.3 Construction of the vector pFV31ilvGM
The E. coli strain FV5069/pFV31 which produces D- pantothenic acid is described in EP-A-0590857 and deposited as FERM BP 4395 in accordance with the Budapest Treaty. The plasmid pFV31 is isolated from FV5069/pFV31, cleaved with the enzyme BamHI, and the projecting 3' ends are treated with Klenow enzyme. An alkaline phosphatase treatment is then carried out. From the vector pTrc99AilvGM described in example 4.2, after restriction with the enzyme Sspl and separation of the cleavage batch in 0.8% agarose gel, the ilvGM expression cassette 2.8 kbp in size is isolated and ligated with the linearized and dephosphorylated vector pFV31. The ligation batch is transformed in the E. coli strain DH5α and plasmid-carrying cells are selected on LB agar, to which 50μg/ml ampicillin are added. Successful cloning of the ilvGM expression cassette can be demonstrated after plasmid DNA isolation and control cleavage with Hindl l, Sail, Smal, Sphl and Xbal. The plasmid is called pFV31ilvGM (figure 3).
I
4.4 Preparation of the strain MG442ΔpckA/pFV31ilvGM
The strain MG442ΔpckA obtained in example 3 and the strain MG442 are transformed with the plasmid pFV31ilvGM and transformants are selected on LB agar, which is supplemented with 50 μg/ml ampicillin. The strains MG442ΔpckA/pFV31ilvGM and MG4 2/pFV31ilvGM are formed in this manner.
4.5 Preparation of D-pantothenic acid with the strain MG442ΔpckA/pFV3lilvGM
The pantothenate production of the E. coli strains MG442/pFV31ilvGM and MG442ΔpckA/pFV31ilvGM is checked in batch cultures of 10 ml contained in 100 ml conical flasks. For this, 10 ml of preculture medium of the following composition: 2 g/1 yeast extract, 10 g/1 (NH) S04, 1 g/1 KH2P04, 0.5 g/1 MgS04*7H20, 15 g/1 CaC03, 20/1 glucose, 50 μg/ml ampicillin, are inoculated with an individual colony and incubated for 20 hours at 33 aC and 200 rpm on an ESR incubator from Kϋhner AG (Birsfelden, Switzerland) . In each case 200 μl of this preculture are transinoculated into 10 ml of production medium (25 g/1 (NH4)2S04, 2 g/1 KH2P04, 1 g/1 MgS04*7H20, 0.03 g/1 FeS04*7H20, 0.018 g/1 MnS04*lH20, 30 g/1 CaC03, 20 g/1 glucose, 20 g/1 β-alanine, 250 mg/1 thiamine) and the batch is incubated for 48 hours at 372C and 200 rpm. After the incubation the optical density (OD) of the culture suspension is determined with an LP2W photometer from Dr. Lange (Dϋsseldorf, Germany) at a measurement wavelength of 660 nm. The concentration of D-pantothenate formed in the sterile- filtered culture supernatant is then determined by means of the Lactobacillus plantarum ATCC8014 pantothenate assay in accordance with the instructions of DIFCO (DIFCO MANUAL, 10th Edition, p. 1100-1102; Michigan, USA). D(+)- Pantothenic acid calcium salt hydrate (catalogue number 25,972-1, Sigma-Aldrich, Deisenhofen, Germany) is used for the calibration.
The result of the experiment is shown in table 1.
Table 1
Brief description of the figures
Figure 1: pMAK705ΔpckA ( = pMAK705deltapckA)
Figure 2: pTrc99AilvGM
Figure 3: pFV31ilvGM
The length data are to be understood as approx. data. The abbreviations and designations used have the following meaning:
• cat: Chloramphenicol resistance gene
• rep-ts: Temperature-sensitive replication region of the plasmid pSClOl
• pckl : Part of the 5 ' region of the pckA gene
• pck2 Part of the 3 ' region of the pckA gene • Amp: Ampicillin resistance gene
• lad: Gene for the repressor protein of the trc promoter
• Ptrc: trc promoter region, IPTG-inducible
• ilvG: Coding region of the large subunit of acetohydroxy acid synthase II
• ilvM: Coding region of the small subunit of acetohydroxy acid synthase II
• 5S: 5S rRNA region
• rrnBT: rRNA terminator region
• panB: Coding region of the panB gene
• panC : Coding region of the panC gene
The abbreviations for the restriction enzymes have the following meaning
• BamHI: Restriction endonuclease from Bacillus amyloliquefaciens
• Bglll: Restriction endonuclease from Bacillus globigii
• Clal: Restriction endonuclease from Caryphanon latum
• EcoRI: Restriction endonuclease from Escherichia coli
• EcoRV: Restriction endonuclease from Escherichia coli
• Hindlll: Restriction endonuclease from Hae ophilus influenzae
• Kpnl: Restriction endonuclease from Klebsiella pneumoniae • Pstl: Restriction endonuclease from Providencia stuartii
• Pvul: Restriction endonuclease from Proteus vulgaris
• Sad: Restriction endonuclease from Streptomyces achromogenes
• Sail: Restriction endonuclease from Streptomyces albus
• Smal: Restriction endonuclease from Serratia marcescens
• Sphl : Restriction endonuclease from Streptomyces phaeochromogenes
• Sspl: Restriction endonuclease from Sphaerotilus species
• Xbal: Restriction endonuclease from Xanthomonas badrii
• Xhol : Restriction endonuclease from Xanthomonas holcicola
BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS""
FOR THE PURPOSES OF PATENT PROCEDURE
INTERNATIONAL FORM
Degussa-Hϋls AG Kantstr. 2 33790 Halle
RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT issued pursuant to Rule 7.1 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page
FormDSMZ-BFM (sole page) 01% BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISM-.
FOR THE PURPOSES OF PATENT PROCEDURE
INTERNATIONAL FORM
Deguasa-Hϋls AG Kantstr. 2 33790 Halle
VIABILITY STATEMENT issued pursuant to Rule 10.2 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page
I. DEPOSITOR II. IDENTIFICATION OF THE MICROORGANISM
Name: Degussa-Hϋls AG Accession number given by the
Kantstr . 2 INTERNATIONAL DEPOSITARY AUTHORITY: Address: 33790 Halle DSM 13720
Date of the deposit or the transfer1: 2000 -09- 08
rπ. VIABILΠΎ STATEMENT
The viability of the microorganism identified under II above was tested on 2 00 0 - 09 - 0 8 On that date, the said. microorganism was
(X)3 viable
( )3 no longer viable rV. CONDITIONS UNDER WHICH THE VIABILITY TEST HAS BEEN PERFORMED4
V. INTERNATIONAL DEPOSITARY AUTHORITY
Name: DSMZ-DEUTSCHE SAMMLUNG VON Signatnre(s) of person(s) having the power to represent the MIKROORGANISMEN UND ZELLKULTUREN GmbH International Depositary Authority or of authorized officials):
Address: Mascheroder eg lb D-38I2 Braunschweig
Date: 2000- 09 - 12
Indicate the date of original deposit or, here a new deposit DI a transfer has been made, the most recent relevant date (date of the new deposit or date of the transfer).
In the cases referred to in Rule 10.2(a) (ii) and (Hi), refer to the most recent viability test
Mark with a cross the applicable box.
Fill in if the information has been requested and if the results of the test were negative.
Form DSMZ-BP/9 (sole page) 0196 BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE
INTERNATIONAL FORM
Degussa-Hϋls AG Kantstr . 2
33790 Halle
RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT issued pursuant to Rule 7.1 by the
INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page
I. IDENTIFICATION OF THE MICROORGANISM
Identification reference given by the DEPOSITOR: Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: MG442ΔpclcA
DSM 13761
E SCIENTIFIC DESCRIPTION AND/OR. PROPOSED TAXONOMIC DESIGNATION
The microorganism identified under I. above was accompanied by:
(X ) a scientific description
(X ) a proposed taxonomic designation
(Mark with a cross where applicable).
in. RECEIPT AND ACCEPTANCE
This International Depositary Authority accepts the microorganism identified under I. above, which was received by it on 2000 - 10 - 02 (Date of the original deposit)1.
rV. RECEIPT OF REQUEST FOR CONVERSION
The microorganism identified under I above was received by this International Depositary Authority on (date of original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on (dale of receipt of request for conversion).
V. INTERNATIONAJL DEPOSITARY AUTHORITY
Name: DSMZ-DEUTSCHE SAMMLUNG VON Signature(s) of person(s) having the power to represent the MIKROORGANISMEN UND ZELLKULTUREN GmbH International Depositary Authority or of authorized officials):
Address: Mascheroder Weg lb D-38124 Braunschweig
Date: 2000 - 10 - 0 6
1 Where Rule 6.4 (d) applies, such date is the date on which the status of international depositary authority was acquired. Form DSMZ-BP/4 (sole page) 0196 BUDAPEST TREATY ON THE INTERNAΗONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS""
FOR THE PURPOSES OF PATENT PROCEDURE
INTERNATIONAL FORM
Degussa-Hϋls AG Kantstr. 2
33790 Halle
VIABILITY STATEMENT issued pursuant to Rule 10.2 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page
I. DEPOSITOR II. IDENTIFICATION OF THE MICROORGANISM
Name: Degussa-Hϋls AG Accession number given by the Kantstr. 2 INTERNATIONAL DEPOSITARY AUTHORITY:
Address: DSM 13761
33790 Halle
Date of the deposit or the transfer': 2000 -10-02
πi. VIABILITY STATEMENT
The viability of the microorganism Identified under II above was tested on 2000 - 10 - 04 On that date, the said microorganism was
(X)3 viable
( Ϋ no longer viable rV. CONDITIONS UNDER WHICH THE VIABILITY TEST HAS BEEN PERFORMED'
V. INTERNATIONAL DEPOSITARY AUTHORITY
Name: DSMZ-DEUTSCHE SAMMLUNG VON Signature© of person(s) having the power to represent the
( MIKROORGANISMEN UND ZELLKULTUREN GmbH International Depositary Authority or of authorized oflϊcial(s):
Address: Mascheroder Weg lb D-3S124 Braunschweig
Date: 2000 - 10 -06
' Indicate the date of original deposit or, where a new deposit or a transfer has been made, the most recent relevant date (date of the new deposit or date of the transfer).
2 In the cases referred to in Rule 10.2(a) (ii) and (iii), refer to the most recent viability test
3 Mark with a cross the applicable box.
' Fill in if the information has been requested and if the results of the test were negative.
Form DSMZ-BP/9 (sole page) 0195

Claims

What is claimed is:
1. Process for the preparation of D-pantothenic acid and/or alkaline earth metal salts thereof or feedstuffs additives comprising these by fermentation of microorganisms of the Enterobacteriaceae family, in particular those which already produce D-pantothenic acid, wherein
a) at least the nucleotide sequence (s) in the microorganisms which code(s) for the pckA gene is
(are) attenuated, in particular eliminated,
b) the D-pantothenic acid and/or salts thereof is (are) concentrated in the medium or in the cells of the microorganisms, and
c) after conclusion of the fermentation, the desired products are isolated, the biomass and/or further constituents of the fermentation broth being left in the product or optionally being separated off completely or in part.
2. Process according to claim 1, wherein the fermentation is carried out in the presence of alkaline earth metal salts, these being added continuously or discontinuously in stoichio etric amounts in particular, and a product comprising alkaline earth metal salts of D-pantothenic acid or consisting of these being obtained.
3. Process according to claim 1 or 2 , wherein the microorganisms of the Enterobacteriaceae family belong to the genus Escherichia.
4. Process according to claim 3 , wherein the microorganisms originate from the genus Escherichia, in particular the species Escherichia coli .
5. Process according to claim 1, wherein in addition to
5. attenuation of the pckA gene, one or more genes, chosen from the group, is (are) enhanced, in particular over- expressed:
5.1 the ilvGM operon which codes for acetohydroxy- acid synthase II,
0 5.2 the panB gene which codes for ketopantoate hydroxymethy1 transferase,
5.3 the panE gene which codes for ketopantoate reductase,
5.4 the panD gene which codes for aspartate 5 decarboxylase,
5.5 the panC gene which codes for pantothenate synthetase,
5.6 the serC gene which codes for phosphoserine transaminase,
0 5.7 the gcvT, gcvH and gcvP genes which code for the glycine cleavage system, individually or together,
5.8 the glyA gene which codes for serine hydroxymethyl transferase.
5 6. Process according to claim 1, wherein bacteria are employed in which the metabolic pathways which reduce the formation of D-pantothenic acid are at least partly eliminated, in particular the
6.1 avtA gene which codes for transaminase C and
6.2 the poxB gene which. codes for pyruvate oxidase.
7. Process according to claim 1, wherein the expression of the polynucleotide (s) which code(s) for the pckA gene is attenuated, in particular eliminated.
8. Process for the preparation of feedstuffs additives comprising D-pantothenic acid and/or salts thereof, according to claim 1, wherein
a) optionally all or some of the biomass and/or a portion of the constituents are separated off from a D-pantothenic acid-containing fermentation broth obtained by fermentation,
b) the mixture obtained in this way is optionally concentrated,' and
c) the feedstuffs additive comprising the pantothenic acid and/or the pantothenate is converted into a free-flowing form by suitable measures, and
d) a free-flowing animal feedstuffs additive with a particle size distribution of 20 to 2000 μm is obtained by suitable measures.
9. Process for the preparation of animal feedstuffs additives according to claim 8 with a content of D- pantothenic acid and/or salts thereof, chosen from the group consisting of the magnesium or calcium salt, in the range from about 20 to 80 wt.% (dry mass) from fermentation broths, comprising the steps of
a) optionally removal of water from the fermentation broth (concentration) .
b) removal of an amount of > 0 to 100% of the biomass formed during the fermentation, c) optionally addition of one or more of the compounds mentioned to the fermentation broths obtained according to a) and b) , the amount of compounds added being such that the total concentration thereof in the animal feedstuffs additive is in the range from about 20 to 80 wt . % , and
d) obtaining of the animal feedstuffs additive in the desired powder or, preferably, granule form.
10. Process according to claim 8, wherein an animal feedstuffs additive with the desired particle size is obtained from the fermentation broth, optionally after addition of D-pantothenic acid and/or salts thereof and optionally after addition of organic and inorganic auxiliary substances, by
a) drying and compacting, or
b) spray drying, or
c) spray drying and granulation, or
d) spray drying and build-up granulation.
11. Microorganisms of the Enterobacteriaceae family which produce pantothenic acid and in which the pckA gene is present in attenuated form.
12. Microorganisms of the Enterobacteriaceae family which produce pantothenic acid and in which the pckA gene is present in eliminated form.
13. Microorganisms of the Enterobacteriaceae family which produce pantothenic acid, according to claim 12, wherein the pckA gene contains a deletion according to SEQ ID No. 8.
EP02706743A 2001-03-14 2002-02-16 Process for the preparation of d-pantothenic acid and/or salts thereof Withdrawn EP1368485A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10112100A DE10112100A1 (en) 2001-03-14 2001-03-14 Process for the fermentative production of D-pantothenic acid and / or its salts
DE10112100 2001-03-14
PCT/EP2002/001677 WO2002072854A2 (en) 2001-03-14 2002-02-16 Process for the preparation of d-pantothenic acid and/or salts thereof

Publications (1)

Publication Number Publication Date
EP1368485A2 true EP1368485A2 (en) 2003-12-10

Family

ID=7677318

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02706743A Withdrawn EP1368485A2 (en) 2001-03-14 2002-02-16 Process for the preparation of d-pantothenic acid and/or salts thereof

Country Status (4)

Country Link
EP (1) EP1368485A2 (en)
AU (1) AU2002240930A1 (en)
DE (1) DE10112100A1 (en)
WO (1) WO2002072854A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE112007001179T5 (en) 2006-05-16 2009-04-02 Dsm Ip Assets B.V. Process for the preparation of panthenol

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0493060A3 (en) * 1990-12-25 1993-04-14 Takeda Chemical Industries, Ltd. Production method of d-pantothenic acid and plasmids and microorganisms thereof
SK30598A3 (en) * 1995-09-13 1999-01-11 Takeda Chemical Industries Ltd Process for producing d-pantoic acid and d-pantothenic acid or salts thereof
DE10026758A1 (en) * 2000-05-30 2001-12-06 Degussa Process for the fermentative production of D-pantothenic acid using corymeform bacteria

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HOU S.-Y. ET AL: "A mutant phosphoenolpyruvate carboxykinase in Escherichia coli conferring oxaloacetate decarboxylase activity", JOURNAL OF BACTERIOLOGY, vol. 177, no. 6, March 1995 (1995-03-01), pages 1620 - 1623 *
See also references of WO02072854A3 *

Also Published As

Publication number Publication date
WO2002072854A2 (en) 2002-09-19
AU2002240930A1 (en) 2002-09-24
WO2002072854A3 (en) 2002-12-05
DE10112100A1 (en) 2002-09-19

Similar Documents

Publication Publication Date Title
US6623944B2 (en) Process for preparation of D-pantothenic acid and/or salts thereof
EP1395662B1 (en) Process for the preparation of d-pantothenic acid and/or salts thereof
WO2002072855A2 (en) Process for the preparation of d-pantothenic acid and/or salts thereof
EP1430139B1 (en) Process for the preparation of d-pantothenic acid and/or its salts
EP1360305B1 (en) A process for the fermentative preparation of d-pantothenic acid and/or its salts
EP1383898B1 (en) A process for the fermentative preparation of d-pantothenic acid and/or its salts
EP1360303A2 (en) Process for the fermentative production of d-pantothenic acid
EP1368485A2 (en) Process for the preparation of d-pantothenic acid and/or salts thereof
US20030073204A1 (en) Process for the manufacture of D-pantothene acid and/or its salts by fermentation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030819

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17Q First examination report despatched

Effective date: 20040211

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050728